Champions Oncology Appoints Rob Brainin as New CEO Amid Expansion Plans.

Champions Oncology (CSBR) has appointed Rob Brainin as new CEO, effective August 25, 2025. Brainin, a former Chief Business Officer at Veracyte, will lead the company's expansion beyond core CRO services. Dr. Ronnie Morris transitions to Executive Chair, while Joel Ackerman becomes Director. The company aims to leverage Brainin's expertise in data capabilities and advance its therapeutics subsidiary, Corellia AI.

HACKENSACK, NJ — Champions Oncology (NASDAQ:CSBR), a leading provider of oncology-focused contract research services, has appointed Rob Brainin as its new Chief Executive Officer, effective August 25, 2025. Brainin, who has served on Champions' Board since 2021, will succeed Dr. Ronnie Morris, who has led the company since 2017. Morris will transition to the role of Executive Chair, remaining actively involved in strategic initiatives.

Brainin brings over 25 years of experience in life sciences and technology, most recently serving as Chief Business Officer at Veracyte, an oncology diagnostics company. He previously held the CEO position at Genuity Science, a genomics and therapeutic discovery firm. The appointment comes as Champions Oncology seeks to expand beyond its core contract research services into data offerings, leveraging Brainin's expertise in scaling businesses built on science and data capabilities.

Current Chairman Joel Ackerman will transition to a Director role, while Dr. Morris will remain actively involved in strategic initiatives as Executive Chair. According to InvestingPro data, Champions Oncology maintains strong operational performance with a 51.6% gross profit margin and 19% revenue growth in the last twelve months. The company operates with moderate debt levels and maintains a "Good" overall financial health rating, with analysts forecasting continued profitability this year.

"I am honored and excited to join Champions at such a pivotal time," said Brainin. "The strength of Champions' core CRO services provides a tremendous foundation to expand our emerging data platform and advance the pipeline of our discovery therapeutics subsidiary, Corellia AI. I look forward to working alongside this talented team to build on the company's momentum and create value for our customers, employees, and shareholders."

The leadership change comes as Champions Oncology aims to build on its established contract research business while developing new data capabilities and advancing its discovery therapeutics subsidiary, Corellia AI. Trading at a P/E ratio of 17.68, which InvestingPro analysis suggests is attractive relative to its growth prospects, Champions Oncology shows promise in its strategic expansion [1].

In other recent news, Champions Oncology has secured a license to utilize radioactive materials in its preclinical studies. This new license enables the company to enhance its capabilities in developing and evaluating targeted radiotherapeutics by conducting in-house research with various radionuclides. This development allows Champions Oncology to integrate radionuclide-based therapeutic testing with its patient-derived xenograft (PDX) models, which are highly clinically relevant. The company aims to advance radiopharmaceutical development with improved translational precision through this integration [2].

References:

[1] https://www.investing.com/news/company-news/champions-oncology-names-rob-brainin-as-new-ceo-93CH-4141767
[2] https://www.marketscreener.com/news/champions-oncology-names-rob-brainin-ceo-ce7c5cdede8df420